Renal Sense, a company that has developed a system for monitoring kidney function in intensive care, has announced a $ 14 million fundraiser. The amount will be used to strengthen the company’s distribution network and expand its product line.
Renal-Sense markets the Clarity RMS product, which is used to monitor kidney function in intensive care. The product continuously measures urine output and transmits the information in real time to the medical staff, including alerts. The goal is primarily to prevent kidney damage during hospitalization. Kidney damage in patients who have undergone significant surgery or treatment in completely different areas, is one of the most problematic side effects that occur in hospitals.
Renell-Sense said the company’s product is installed in dozens of operating rooms, general intensive care units, heart transplant centers and corona wards, in the US, Europe and Israel. And other vital organs.So the market may grow beyond intensive care.
The fundraising is led by the Blue Red Partners fund and is attended by several family funds involved in the field of healthcare and existing shareholders who have previously invested in the company. BlueRed Partners is an investment fund from Singapore that focuses on Israeli technology companies that are in the growth stages, and offer solutions with potential in response to future needs and trends in the Asian market.
New cooperation agreements in Europe, Israel and Taiwan
Renal-Sense was founded in the Maayan Ventures incubator in 2010, by Dr. Moore Greenstein, now a physician at Mass General Hospital in Boston and a lecturer at Harvard in the field of acquired kidney failure, and Avi Kleiman, who previously founded several medical device companies, who directs Today, the company has strategic network partners, and distribution partnerships that include Fresenius Medical Care (Europe), Medline (North America) and Gloryway (China). With PAHSCO.
“Renal-Sense is at the forefront of the realization of real-time renal monitoring, providing intensive care teams with a critical indicator of vital organ function that has not been accessed in the past,” said Yishai Klein, managing partner and co-founder of BlueRed Partners. “More and more leading medical centers in the US and Europe are adopting the system, and we will support the company’s growth as it expands its range of operations to Asia and expands its product line.”
“With the recent publication of clinical articles proving the importance of the Clarity RMS system in intensive care, we are expanding validation to other areas as well, such as cardiology and anesthesia, while developing a product line based on our sensors,” Kleiman said. “We welcome the joining of new investors, who share our vision and understand the importance of real-time digital monitoring of kidney function, which gives this index a value equal to that of all vital signs (blood pressure, pulse, etc.) among hospitalized patients.”